Health Canada approves Orfadin® capsules for the treatment of hereditary tyrosinaemia type-1 (HT-1)
Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces that Health Canada has approved Orfadin® (nitisinone) capsules for the treatment of hereditary tyrosinaemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine. HT-1 is a progressive, rare genetic disease that may result in liver and kidney complications and in most cases fatal if untreated. In the most common form of the disease, symptoms arise within the first six months of the child's life. Orfadin capsules will now be available in Canada in a wide range of dosing options;